Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
Yuanchao Xie, Wanchao Yin, Yumin Zhang, et al.
Cell Research (2021) Vol. 31, Iss. 11, pp. 1212-1214
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

Deuterium in drug discovery: progress, opportunities and challenges
Rita Maria Concetta Di Martino, Brad D. Maxwell, Tracey Pirali
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 562-584
Open Access | Times Cited: 230
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
Zhujun Cao, Weiyi Gao, Hong Bao, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 5, pp. 406-417
Open Access | Times Cited: 187
Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
Canrong Wu, Wanchao Yin, Yi Jiang, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 12, pp. 3021-3033
Open Access | Times Cited: 103
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 103
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 79
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants
Chong Huang, Huiping Shuai, Jingxin Qiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 50
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
Yinzhong Shen, Jingwen Ai, Na Lin, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1518-1523
Open Access | Times Cited: 61
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
Hongjie Qian, Yu Wang, Mengqi Zhang, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 12, pp. 3130-3138
Open Access | Times Cited: 57
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, et al.
Health Science Reports (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 38
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115292-115292
Open Access | Times Cited: 26
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
Xiaohong Fan, Xiahong Dai, Yun Ling, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 2, pp. 129-139
Closed Access | Times Cited: 25
Preparing for the next viral threat with broad-spectrum antivirals
Marwah Karim, Chieh‐Wen Lo, Shirit Einav
Journal of Clinical Investigation (2023) Vol. 133, Iss. 11
Open Access | Times Cited: 24
Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19
Ke‐Wei Zhu
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1306-1309
Open Access | Times Cited: 24
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Coronaviral RNA-methyltransferases: function, structure and inhibition
Radim Nencka, Jan Šilhán, Martin Klíma, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. 2, pp. 635-650
Open Access | Times Cited: 52
Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges
Zhonglei Wang, Liyan Yang
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1373-1390
Closed Access | Times Cited: 43
Deuterated Drugs and Biomarkers in the COVID-19 Pandemic
Ross D. Jansen‐van Vuuren, Luka Jedlovčnik, Janez Košmrlj, et al.
ACS Omega (2022) Vol. 7, Iss. 46, pp. 41840-41858
Open Access | Times Cited: 36
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
Liu Cao, Yingjun Li, Sidi Yang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 661
Open Access | Times Cited: 30
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, et al.
Pharmacological Research (2022) Vol. 179, pp. 106201-106201
Open Access | Times Cited: 29
A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity
Junyu Yang, Yixuan Ma, Yan Liu, et al.
Molecules (2023) Vol. 28, Iss. 6, pp. 2735-2735
Open Access | Times Cited: 20
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
Zhitao Yang, Yu Xu, Ruizhi Zheng, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241765-e241765
Open Access | Times Cited: 7
Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuan‐Qin Min, Wei Xiong, Wei Shen, et al.
Science Advances (2024) Vol. 10, Iss. 15
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top